Biotronik announced that a drug-eluting stent system for the treatment of patients with CAD has been approved by the FDA and is commercially available in the U.S.

The DES (Orsiro, Biotronik) is used during PCI and elutes sirolimus through a bioabsorbable polymer coating (Biolute, Biotronik), according to a press release from the company. The system also has a coating that reduces nickel ion release, ultrathin stent struts and a low crossing profile.